{"id":"https://openalex.org/W7225752897","doi":"https://doi.org/10.25251/nr1kv966","title":"Real-World Safety of Upadacitinib in Adults and Adolescents With Atopic Dermatitis: 12-Month Analysis of the Multicountry Observational AD-VISE Study","display_name":"Real-World Safety of Upadacitinib in Adults and Adolescents With Atopic Dermatitis: 12-Month Analysis of the Multicountry Observational AD-VISE Study","publication_year":2026,"publication_date":"2026-11-10","ids":{"openalex":"https://openalex.org/W7225752897","doi":"https://doi.org/10.25251/nr1kv966"},"language":"en","primary_location":{"id":"doi:10.25251/nr1kv966","doi":"https://doi.org/10.25251/nr1kv966","is_oa":true,"landing_page_url":"https://doi.org/10.25251/nr1kv966","pdf_url":null,"source":{"id":"https://openalex.org/S4210210594","display_name":"SKIN The Journal of Cutaneous Medicine","issn_l":"2574-1624","issn":["2574-1624"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","poland-20"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"SKIN The Journal of Cutaneous Medicine","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj"],"open_access":{"is_oa":true,"oa_status":"diamond","oa_url":"https://doi.org/10.25251/nr1kv966","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5021906179","display_name":"Charles W Lynde","orcid":"https://orcid.org/0000-0001-9163-5463","observed_orcids":["https://orcid.org/0000-0001-9163-5463"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Charles Lynde","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060517084","display_name":"Ahmed Ameen","orcid":"https://orcid.org/0009-0002-7371-4509","observed_orcids":["https://orcid.org/0009-0002-7371-4509"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ahmed Ameen","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5030082080","display_name":"Hermenio Lima","orcid":"https://orcid.org/0000-0003-0950-3731","observed_orcids":["https://orcid.org/0000-0003-0950-3731"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Hermenio Lima","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035044854","display_name":"Rodney Daniel Sinclair","orcid":"https://orcid.org/0000-0001-6751-1428","observed_orcids":["https://orcid.org/0000-0001-6751-1428"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Rodney Sinclair","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078299066","display_name":"Filip Rob","orcid":"https://orcid.org/0000-0001-5257-205X","observed_orcids":["https://orcid.org/0000-0001-5257-205X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Filip Rob","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5067671033","display_name":"Elena Pezzolo","orcid":"https://orcid.org/0000-0003-0121-4812","observed_orcids":["https://orcid.org/0000-0003-0121-4812"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Elena Pezzolo","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5161374604","display_name":"Chin-Yi Yang","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Chin-Yi Yang","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5138199262","display_name":"Elisabeth Lazaridou","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Elisabeth Lazaridou","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5128645052","display_name":"Michael Lane","orcid":"https://orcid.org/0009-0006-4161-1467","observed_orcids":["https://orcid.org/0009-0006-4161-1467"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Michael Lane","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004732852","display_name":"David Pr\u00e9fontaine","orcid":"https://orcid.org/0009-0001-8568-0775","observed_orcids":["https://orcid.org/0009-0001-8568-0775","https://orcid.org/0000-0002-5021-1637"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"David Prefontaine","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5006526834","display_name":"Melinda Gooderham","orcid":"https://orcid.org/0000-0001-8926-0113","observed_orcids":["https://orcid.org/0000-0001-8926-0113"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Melinda Gooderham","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"10","issue":"6","first_page":"804","last_page":"804"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10837","display_name":"Dermatology and Skin Diseases","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10837","display_name":"Dermatology and Skin Diseases","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11117","display_name":"Drug-Induced Adverse Reactions","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11033","display_name":"Contact Dermatitis and Allergies","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9258999824523926},{"id":"https://openalex.org/C2778715236","wikidata":"https://www.wikidata.org/wiki/Q55622662","display_name":"Discontinuation","level":2,"score":0.7983999848365784},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.6635000109672546},{"id":"https://openalex.org/C23131810","wikidata":"https://www.wikidata.org/wiki/Q818574","display_name":"Observational study","level":2,"score":0.6338000297546387},{"id":"https://openalex.org/C61511704","wikidata":"https://www.wikidata.org/wiki/Q1671857","display_name":"Incidence (geometry)","level":2,"score":0.47369998693466187},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.46309998631477356},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4575999975204468},{"id":"https://openalex.org/C2778329239","wikidata":"https://www.wikidata.org/wiki/Q268667","display_name":"Atopic dermatitis","level":2,"score":0.4512999951839447},{"id":"https://openalex.org/C72563966","wikidata":"https://www.wikidata.org/wiki/Q1303415","display_name":"Cohort","level":2,"score":0.4397999942302704},{"id":"https://openalex.org/C201903717","wikidata":"https://www.wikidata.org/wiki/Q1778788","display_name":"Cohort study","level":2,"score":0.43970000743865967},{"id":"https://openalex.org/C3018359032","wikidata":"https://www.wikidata.org/wiki/Q1550789","display_name":"Safety profile","level":3,"score":0.41519999504089355},{"id":"https://openalex.org/C187212893","wikidata":"https://www.wikidata.org/wiki/Q123028","display_name":"Pediatrics","level":1,"score":0.40149998664855957},{"id":"https://openalex.org/C2776233030","wikidata":"https://www.wikidata.org/wiki/Q17149812","display_name":"Janus kinase inhibitor","level":4,"score":0.39730000495910645},{"id":"https://openalex.org/C205545832","wikidata":"https://www.wikidata.org/wiki/Q17156455","display_name":"Young adult","level":2,"score":0.30649998784065247},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.3021000027656555},{"id":"https://openalex.org/C167135981","wikidata":"https://www.wikidata.org/wiki/Q2146302","display_name":"Retrospective cohort study","level":2,"score":0.2703000009059906},{"id":"https://openalex.org/C23276603","wikidata":"https://www.wikidata.org/wiki/Q158230","display_name":"Pharmacoepidemiology","level":3,"score":0.25609999895095825},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.250900000333786}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.25251/nr1kv966","doi":"https://doi.org/10.25251/nr1kv966","is_oa":true,"landing_page_url":"https://doi.org/10.25251/nr1kv966","pdf_url":null,"source":{"id":"https://openalex.org/S4210210594","display_name":"SKIN The Journal of Cutaneous Medicine","issn_l":"2574-1624","issn":["2574-1624"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","poland-20"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"SKIN The Journal of Cutaneous Medicine","raw_type":"journal-article"}],"best_oa_location":{"id":"doi:10.25251/nr1kv966","doi":"https://doi.org/10.25251/nr1kv966","is_oa":true,"landing_page_url":"https://doi.org/10.25251/nr1kv966","pdf_url":null,"source":{"id":"https://openalex.org/S4210210594","display_name":"SKIN The Journal of Cutaneous Medicine","issn_l":"2574-1624","issn":["2574-1624"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","poland-20"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"SKIN The Journal of Cutaneous Medicine","raw_type":"journal-article"},"sustainable_development_goals":[],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":4,"referenced_works":["https://openalex.org/W3193360717","https://openalex.org/W4220831188","https://openalex.org/W4286254610","https://openalex.org/W4416238681"],"related_works":[],"abstract_inverted_index":{"Introduction:":[0],"Upadacitinib":[1],"(UPA)":[2],"is":[3,40,95],"an":[4,96,167,192],"oral":[5],"selective":[6],"Janus":[7],"kinase":[8],"inhibitor":[9],"approved":[10],"for":[11,34,182],"the":[12,28,35,61,77,90,104,127,135,143,201,427,439],"treatment":[13,36,86],"of":[14,32,37,47,85,106,121,137,139,164,187,191,212,215,221,246,275,292,309,337,367,389,426,430],"atopic":[15,390],"dermatitis":[16,391],"(AD)":[17],"in":[18,49,71,112,364,432,446,450],"adolescents":[19,115],"and":[20,30,51,109,114,162,171,209,252,263,343,417],"adults.":[21],"Multiple":[22],"clinical":[23,72,451],"trials":[24],"have":[25,64],"reported":[26,57,70,159,316,348,361],"on":[27],"efficacy":[29],"safety":[31,80,129,429,444],"UPA":[33,48,88,107,140,144,197,276,294,431,442],"AD.":[38,55],"AD-VISE":[39,62,91,94],"a":[41,119,210,289],"real-world":[42,79,428],"drug":[43],"utilization":[44],"cohort":[45],"study":[46,63,101],"adolescent":[50],"adult":[52],"patients":[53,131,165,183,208,226,237,324,433,447],"with":[54,87,116,232,243,288,434,438,448],"Previously":[56],"effectiveness":[58,105],"analyses":[59],"from":[60,89],"shown":[65],"similar":[66],"trends":[67],"to":[68,196,217,249,273],"those":[69],"trials.":[73,452],"Here":[74],"we":[75,125],"present":[76],"first":[78],"data":[81],"through":[82],"12":[83],"months":[84],"study.":[92],"Methods:":[93],"ongoing":[97],"observational,":[98],"prospective,":[99],"multi-country":[100],"primarily":[102],"evaluating":[103],"(15":[108],"30":[110,148,264],"mg)":[111],"adults":[113],"AD":[117,435,449],"over":[118],"period":[120],"2":[122],"years.":[123],"Herein,":[124],"report":[126],"12-month":[128],"analysis,":[130],"were":[132,255,277,296,315,346,372],"followed":[133],"until":[134],"earliest":[136],"one-year":[138],"exposure":[141,172,216],"or":[142,307,387],"discontinuation":[145,274],"date":[146],"plus":[147],"days":[149],"(data":[150],"cutoff:":[151],"Oct":[152],"17,":[153],"2025).":[154],"Adverse":[155],"events":[156],"(AEs)":[157],"are":[158,436],"as":[160],"number":[161],"percentage":[163],"experiencing":[166,238],"AE":[168,193,242],"(n,":[169],"%),":[170],"adjusted":[173],"event":[174,331],"rate":[175],"(events":[176],"[E]":[177],"per":[178],"100":[179],"patient-years":[180],"[PYs])":[181],"receiving":[184],"any":[185],"dose":[186],"UPA.":[188,218,250],"The":[189,358],"possibility":[190,245,291],"being":[194,247,293],"related":[195,248,295],"was":[198],"assessed":[199],"by":[200,257,279,298,369],"investigators.":[202],"Results:":[203],"This":[204],"analysis":[205],"included":[206],"861":[207],"total":[211,220],"757.4":[213],"PYs":[214],"A":[219],"441":[222],"(51.2%;":[223],"171.0":[224],"E/100PYs)":[225,236],"experienced":[227,256,278,297,325],"at":[228,239,326],"least":[229,240,327],"one":[230,241,328],"AE,":[231],"284":[233],"(33.0%;":[234],"74.1":[235],"reasonable":[244,290],"Serious":[251,286],"severe":[253],"AEs":[254,271,287,362],"33":[258],"(3.8%;":[259],"6.7":[260],"E/100":[261,267,283,302,334,356],"PYs)":[262,268,284,303],"(3.5%;":[265],"5.8":[266],"patients,":[269,368],"respectively.":[270],"leading":[272],"38":[280],"(4.4%;":[281],"8.3":[282],"patients.":[285,304],"10":[299],"(1.2%;":[300],"2.5":[301],"No":[305],"deaths":[306],"cases":[308],"malignancy":[310],"excluding":[311],"non-melanoma":[312],"skin":[313],"cancer":[314],"(n":[317,374,382,392,397,403,408,413,419],"=":[318,321,352,375,383,393,398,404,409,414,420],"0;":[319],"E":[320],"0).":[322],"Nineteen":[323],"herpes":[329,401],"zoster":[330],"(2.2%;":[332],"2.8":[333],"PYs).":[335,357],"Cases":[336],"lymphoma,":[338],"major":[339],"adverse":[340],"cardiovascular":[341],"events,":[342],"venous":[344],"thromboembolism":[345],"each":[347],"once":[349],"(each":[350],"n":[351],"1,":[353],"0.1%;":[354],"0.1":[355],"most":[359],"commonly":[360],"(occurring":[363],"\u2265":[365],"2%":[366],"preferred":[370],"term)":[371],"acne":[373],"94,":[376],"10.9%),":[377],"upper":[378],"respiratory":[379],"tract":[380],"infection":[381],"61,":[384],"7.1%),":[385],"continued":[386],"worsening":[388],"60,":[394],"7.0.%),":[395],"COVID-19":[396],"58,":[399],"6.7%),":[400],"simplex":[402],"23,":[405],"2.7%),":[406],"headache":[407],"22,":[410],"2.6%),":[411],"nasopharyngitis":[412],"21,":[415],"2.4%),":[416],"folliculitis":[418],"18,":[421],"2.1%).":[422],"Conclusion:":[423],"These":[424],"results":[425],"consistent":[437],"previously":[440],"established":[441],"long-term":[443],"profile":[445]},"counts_by_year":[],"updated_date":"2026-11-11T12:16:26.678958","created_date":"2026-11-11T00:00:00"}